High drug costs exclude most neurology patients from cutting-edge treatmentDecember 5, 2022Multiple Sclerosis
MS bears no effect on certain pregnancy complications, stillbirth, or congenital deformationFebruary 5, 2021Multiple Sclerosis
Is the EDSS an adequate outcome measure in secondary progressive MS trials?January 29, 2021Multiple Sclerosis
In MS, serious adverse effects are more common in rituximab versus ocrelizumabSeptember 11, 2020Multiple Sclerosis
Lowering rituximab dose in patients with MS proves safe and effectiveSeptember 9, 2020Multiple Sclerosis
